Dr. Peter O'Donnell, MD
Claim this profileUniversity of Chicago
Studies Bladder Cancer
Studies Transitional Cell Carcinoma
6 reported clinical trials
13 drugs studied
Area of expertise
1Bladder Cancer
Stage III
HER2 positive
Stage IV
2Transitional Cell Carcinoma
Stage III
HER2 positive
Stage IV
Affiliated Hospitals
Clinical Trials Peter O'Donnell, MD is currently running
Genetic Testing
for Surgery
The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago. At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS). Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients. There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).
Recruiting1 award N/A
Pharmacogenomic Testing
for Cancer Care
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications. This is a randomized study, which means that participants in this study will be randomly assigned (as if "by flip of a coin") to one of two different groups: a "pharmacogenomics group" or "control group".
Recruiting1 award N/A2 criteria
More about Peter O'Donnell, MD
Clinical Trial Related7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Peter O'Donnell, MD has experience with
- Atezolizumab
- Gemcitabine
- Cisplatin
- Disitamab Vedotin
- Pembrolizumab
- Pharmacogenomics (PGx) Testing And Genomics Prescribing Information (GPS)
Breakdown of trials Peter O'Donnell, MD has run
Bladder Cancer
Transitional Cell Carcinoma
Locally Advanced
Unresectable
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter O'Donnell, MD specialize in?
Peter O'Donnell, MD focuses on Bladder Cancer and Transitional Cell Carcinoma. In particular, much of their work with Bladder Cancer has involved Stage III patients, or patients who are HER2 positive.
Is Peter O'Donnell, MD currently recruiting for clinical trials?
Yes, Peter O'Donnell, MD is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Peter O'Donnell, MD has studied deeply?
Yes, Peter O'Donnell, MD has studied treatments such as Atezolizumab, Gemcitabine, Cisplatin.
What is the best way to schedule an appointment with Peter O'Donnell, MD?
Apply for one of the trials that Peter O'Donnell, MD is conducting.
What is the office address of Peter O'Donnell, MD?
The office of Peter O'Donnell, MD is located at: University of Chicago, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.